Pharmaceutical

Dexmedetomidine by Teikoku Pharma USA for Post-Operative Pain: Likelihood of Approval

Dexmedetomidine is under clinical development by Teikoku Pharma USA and currently in Phase II for Post-Operative Pain.

Jul 7, 2023 - 20:00
Dexmedetomidine is under clinical development by Teikoku Pharma USA and currently in Phase II for Post-Operative Pain.
Read the original article

Tags:

Previous Article

Oncolytic Virus for Human Papillomavirus Associated Cancer, Human Papillomavirus...

Next Article

FDA dismisses Amneal’s Parkinson’s candidate

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Amy Abernethy to step down as Verily’s chief medical officer in latest departure from company

STAT+: Amy Abernethy to step down as Verily’s chief med...

Dec 19, 2023

Keytruda remains Merck & Co’s biggest 2023 success story as patent expiry looms

Keytruda remains Merck & Co’s biggest 2023 success stor...

Feb 2, 2024

Opinion: What does it mean to be ‘in recovery’? We need a better federal definition

Opinion: What does it mean to be ‘in recovery’? We need...

Jul 12, 2023